Table 2.
Distribution of patients by pre-operative oncologic characteristics
| Characteristic | n | % |
|---|---|---|
| All | 34 | |
| PSA at Primary Diagnosis | ||
| <4.0ng/ml | 1 | 3% |
| 4.0-10.0ng/ml | 20 | 59% |
| >10.0ng/ml | 4 | 12% |
| Gleason Score at Primary Diagnosis | ||
| 6 | 15 | 44% |
| 7 | 9 | 26% |
| ≥8 | 1 | 3% |
| Pre-operative Local Therapy | ||
| Brachytherapy | 13 | 38% |
| XRT | 11 | 32% |
| Brachytherapy/XRT | 6 | 18% |
| HIFU | 4 | 12% |
| PSA Doubling Time | ||
| <3.0 months | 1 | 3% |
| 3.0-8.9 months | 11 | 32% |
| 9.0-14.9 months | 11 | 32% |
| >15 months | 5 | 15% |
| PSA at sRALP | ||
| <4.0ng/ml | 17 | 50% |
| 4.0-10.0ng/ml | 15 | 44% |
| >10.0ng/ml | 2 | 6% |
| Pre-operative Biopsy Gleason Score | ||
| 6 | 13 | 38% |
| 7 | 8 | 24% |
| ≥8 | 12 | 35% |
| T Clinical Stage | ||
| T1 | 22 | 65% |
| T2 | 10 | 29% |
| ≥T3 | 2 | 6% |
| Time to sRALP | ||
| <24 months | 3 | 9% |
| 24-36 months | 11 | 32% |
| 37-48 months | 3 | 9% |
| 49-60 months | 6 | 18% |
| >60 months | 11 | 32% |
Percentages may not add up to 100% due to missing data.